![Ravi Madan: Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing](https://oncodaily.com/pub/uploads/2024/07/Pi7_Tool_Iu8_59Eo_400x400-e1720700396771.jpg)
Photo from Ravi Madan/X
Jul 11, 2024, 12:34
Ravi Madan: Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing
Ravi Madan, Clinical researcher focused on Prostate Cancer at National Cancer Institute, shared a post on X: .
“Now online. European Urology Oncology: Enzalutamide Monotherapy in EMBARK BCR Prostate Cancer Should Be Practice-changing, and Existing Data Suggest How to Mitigate Toxicity.”
Visit the article website.
Source: Ravi Madan/X